Sunshine Biopharma Inc.
SBFM Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.65
KIRA · Stoqly’s AI analyst, in plain words
- Sunshine Biopharma Inc. had $36.3M of revenue in fiscal 2025, up 4.1% on the year before. Over five years, revenue changed +247.7% a year on average.
- Its operating margin was −17.2%, down 0.5 pts: of every 100 in sales, about −17 is left after running the business.
- Sunshine Biopharma Inc. lost $6.0M in fiscal 2025.
- Free cash flow was −$5.5M in fiscal 2025, −15.2% of revenue.
- Sunshine Biopharma Inc. returned $0.0M to shareholders in fiscal 2025.
Market cap
—
P/E
—
Revenue
$36.3M
Net income
−$6.0M
Free cash flow
−$5.5M
Operating margin
−17.2%
Sunshine Biopharma Inc. in 30 seconds · fiscal 2025
Are sales growing?
+4.1%
Only a little. Sales grew 4.1% last year.
Does it make a profit?
−16.5%
No. It lost money last year.
Does profit turn into cash?
−15.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
What Sunshine Biopharma Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 3, 2026
- Legal name
- Sunshine Biopharma Inc.
- CIK
- 0001402328
Sunshine Biopharma Inc. · SBFM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.2M | $4.3M | $24.1M | $34.9M | $36.3M |
| Revenue growth | 219.9% | 1,802.6% | 454.4% | 44.7% | 4.1% |
| Gross margin | 48.4% | 39.0% | 34.6% | 30.6% | 33.8% |
| Operating margin | −1,068.3% | −621.3% | −19.9% | −16.7% | −17.2% |
| Net income | −$12.4M | −$26.7M | −$4.5M | −$5.1M | −$6.0M |
| Net margin | −5,445.0% | −615.4% | −18.7% | −14.7% | −16.5% |
| Diluted EPS | −$4.76 | −$1.76 | −$351.36 | −$7.32 | — |
| Cash | |||||
| Cash from operations | −$1.8M | −$5.2M | −$8.8M | −$12.5M | −$5.3M |
| Capital expenditure | $0.0M | $0.2M | $0.1M | $1.7M | $0.2M |
| Free cash flow | −$1.8M | −$5.4M | −$8.9M | −$14.2M | −$5.5M |
| FCF margin | −800.8% | −125.2% | −36.8% | −40.7% | −15.2% |
| Share buybacks | — | — | $0.5M | $3.1M | $0.0M |
| Share count change | — | 481.2% | −99.9% | 5,382.0% | — |
| Debt and strength | |||||
| Cash and short-term investments | $2.0M | $21.8M | $16.3M | $9.7M | $9.1M |
| Shareholders' equity | $0.2M | $21.6M | $21.2M | $23.5M | $23.0M |
| Current ratio | 24.1x | 3.9x | 4.5x | 4.1x | 4.2x |
| Interest coverage | −7.4x | −685.3x | −34.9x | −660.5x | — |
| Returns and quality | |||||
| Return on equity | — | −244.9% | −21.0% | −23.0% | −25.7% |
| Return on tangible equity | −5,874.5% | −128.3% | −22.8% | −25.1% | −28.3% |
| Piotroski F-score | 3 | 3 | 4 | 1 | 4 |
| Altman Z'' | −49.4 | −5.3 | −0.5 | −0.9 | −1.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sunshine Biopharma Inc. · SBFM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.65 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001402328). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.